Interleukin-1-receptor antagonist in type 2 diabetes mellitus

New England Journal of Medicine

Volumn 356, Issue 15, 2007, Pages 1517-1526

  Larsen, Claus M ^a   Faulenbach, Mirjam ^c   Vaag, Allan ^a,e   Vølund, Aage ^b   Ehses, Jan A ^c   Seifert, Burkhardt ^d   Mandrup Poulsen, Thomas ^a,f   Donath, Marc Y ^c  

^a STENO DIABETES CENTER   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e LUND UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C REACTIVE PROTEIN; GLUCAGON; GLUCOSE; HEMOGLOBIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; GLUCOSE TRANSPORTER 4; GLYCOSYLATED HEMOGLOBIN; HEAT SHOCK PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; PPARGC1A PROTEIN, HUMAN; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FACIAL NERVE PARALYSIS; FEMALE; FOOT DISEASE; FOOT INFECTION; GLUCOSE TOLERANCE TEST; HEMATOMA; HUMAN; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PERONEUS NERVE PARALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINARY TRACT INFECTION; BLOOD; BODY MASS; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHYSIOLOGY; SECRETION;

BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; HEAT-SHOCK PROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 34247170807     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa065213     Document Type: Article

References (28)

1. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs: genetic control of insulin response? Acta Endocrinol (Copenh) 1967;55:330-45.
2. DeFronzo RA. Lilly Lecture 1987. The triumvirate: beta-cell, muscle, liver - a collusion responsible for NIDDM. Diabetes 1988;37:667-87.
3. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16 - overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58. [Erratum, Diabetes 1996;45:1655.]
4. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-10.
5. Hellerstrom C. The life story of the pancreatic B cell. Diabetologia 1984;26:393-400.
6. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004;47:581-9.
7. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
8. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996;39:1005-29.
9. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986;232:1545-7.
10. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta-cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60.
11. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces beta-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 2001;50:1683-90.
12. Maedler K, Storling J, Sturis J, et al. Glucose- and interleukin-1beta- induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004;53:1706-13.
13. Welsh N, Cnop M, Kharroubi I, et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes 2005;54:3238-44.
14. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732-4.
15. Zumsteg U, Reimers JI, Pociot F, et al. Differential interleukin-1 receptor antagonism on pancreatic beta and alpha cells: studies in rodent and human islets and in normal rats. Diabetologia 1993;36:759-66.
16. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004;101:8138-43.
17. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29:Suppl 1:S43-S48.
18. Vaag A, Alford F, Henriksen FL, Christopher M, Beck-Nielsen H. Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM. Diabetologia 1995;38:326-36.
19. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately down regulated in human diabetes. Nat Genet 2003;34:267-73.
20. Ling C, Poulsen P, Carlsson E, et al. Multiple environmental and genetic factors influence skeletal muscle PGC-1alpha and PGC-1beta gene expression in twins. J Clin Invest 2004;114:1518-26.
21. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993;39:578-82.
22. Hartling SG, Dinesen B, Kappelgard AM, Faber OK, Binder C. ELISA for human proinsulin. Clin Chim Acta 1986;156:289-97.
23. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975;11:541-8.
24. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
25. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006;355:581-92.
26. Garcia MC, Wernstedt I, Berndtsson A, et al. Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 2006;55:1205-13.
27. Chida D, Osaka T, Hashimoto O, Iwakura Y. Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes 2006;55:971-7.
28. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005;52:1960-7.